← Leaderboards
Eric E Swayze
Isis Pharmaceuticals, Inc.
$2,149,351
Attributed
$2,149,351
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $482.6K · FY2006–09$500K$375K$250K$125K$0
'06
'07
'08
'09
Funding mix
By agency
NIH$2,149,351 · 3
By mechanism
R44$2,050,164 · 2
R43$99,187 · 1
Top collaborators
No co-investigators on record.
Most similar at Isis Pharmaceuticals, Inc.
Same institution · by research overlap
- Lawrence B Blyn$5,462,112
Others in their field
Top investigators on “Evaluation”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- David Heimbrook · Leidos Biomedical Research, Inc.$564,050,020
- Lawrence Corey · Fred Hutchinson Cancer Center$559,122,174
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,869,793
- Jeffrey P Krischer · University Of South Florida$466,087,841
- Judith S. Currier · University Of California Los Angeles$403,175,569
Research focus
EvaluationGenesDrug Delivery SystemsDrug KineticsGene ExpressionBaseDesignDoseAnalogDrug DesignExhibitsExplosionCell PhysiologyCell ProliferationCellsAnimal ModelBiologicalChemotherapy-Oncologic ProcedureBiological ModelsClinical TrialsBloodComplexAnimalsGovernment
Grant awards (6)
Chemical Modifications to Improve RNAi Drugs$463,365
R44 · FY2009 · GM · contact PI
Chemical Modifications to Improve RNAi Drugs$464,156
R44 · FY2008 · GM · contact PI
Chemical Modifications to Improve RNAi Drugs$482,643
R44 · FY2007 · GM · contact PI
Chemical Modification to Improve siRNA Pharmacokinetics in Animals$99,187
R43 · FY2006 · GM · contact PI
Antimicrobial agents directed against L11/23S rRNA$375,000
R44 · FY2002 · AI
Antimicrobial agents directed against L11/23S rRNA$265,000
R44 · FY2001 · AI